CD274 and breast carcinoma: To the best of our knowledge, this is the first time a GR@IO-based bioprobe combined with a PD-L1 antibody has been developed to qualitatively distinguish PD-L1 expression in breast cancer cells based on SERS-MRI dual-modal bioprobes in vitro and in vivo.